FX.co ★ Ionis' Olezarsen Receives FDA Orphan Drug Designation

Ionis Pharmaceuticals, Inc. announced on Thursday that the FDA has awarded Orphan Drug status to its investigational drug, Olezarsen. This drug aims to tackle familial chylomicronemia syndrome, a rare genetic condition characterized by unusually high levels of triglycerides and recurrent acute pancreatitis episodes. The company also shared details about its active Phase 3 trials to test the efficacy of Olezarsen in treating not just severe hypertriglyceridemia but also FCS.